PLEURAL DISEASES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Pleural diseases encompass a diverse group of conditions affecting the pleura, the thin membrane surrounding the lungs. These conditions can significantly impact respiratory function and overall well-being. The pleura plays a crucial role in maintaining the integrity of the lung’s structure and function by providing lubrication and allowing smooth movement during breathing. Pleural diseases can arise from various causes, including infections, inflammation, tumors, and exposure to hazardous substances. Common pleural disorders include pleurisy, pleural effusion, pneumothorax and mesothelioma. Recognizing the symptoms, diagnosing accurately, and implementing appropriate treatment strategies are essential in managing and improving outcomes for individuals affected by these challenging global pleural diseases. The global global pleural diseases market has been steadily growing over the years driven by the rising prevalence of associated risk factors such as smoking, tuberculosis, and metastases. Furthermore, the market has witnessed significant technological advancements in diagnosis and treatment modalities such as imaging techniques and laser therapy, further supporting the market growth.

Market Dynamics:

The increasing adoption of inorganic strategies such as agreement is also expected to drive the growth of the market over the forecast period. For instance, in November 2020, Taiho Pharmaceutical Co., Ltd, a pharmaceutical company, and Lung Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Japan.

However, limited awareness and delayed diagnosis, cost of diagnostic tools and treatment, limited availability of expertise and resources are expected to hamper growth of the global pleural diseases market over the forecast period.

 Key features of the study:

• This report provides an in-depth analysis of the global pleural diseases market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2026-2033, considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Global Pleural Diseases market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., B. Braun SE, Becton, Dickinson and Company, Bicakcilar, Biometrix, Cook Medical, Grena, Redax, Rocket Medical, Smith Medical.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global pleural diseases market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pleural diseases market

Global Pleural Diseases Market Segmentation (Version-2026) Detailed Segmentation:

• By Disease Types (Revenue, USD Bn, 2021 - 2033)
  • Pleurisy
  • Pleural Effusion
  • Pneumothelioma
  • Mesothelioma
  • Others
• By Diagnostic Tools (Revenue, USD Bn, 2021 - 2033)
  • Imaging Techniques
  • Molecular Diagnostics
  • Thoracoscopy and Pleuroscopy
• By Treatment Modalities (Revenue, USD Bn, 2021 - 2033)
  • Medications
  • Thoracentesis and Pleurodesis
  • Minimally Invasive Interventions
  • Surgical Interventions
• By End User (Revenue, USD Bn, 2021 - 2033)
  • Hospitals and Clinics
  • Diagnostic Centers
  • Research and Academic Institutions

• Regional Insights (Revenue, USD Bn, 2021 - 2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Company Profile:
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • AbbVie Inc.
  • Braun SE
  • Becton, Dickinson and Company
  • Bicakcilar
  • Biometrix
  • Cook Medical
  • Grena
  • Redax
  • Rocket Medical
  • Smith Medical